NeurOp

NeurOp develops medicine to treat central nervous system disorders such as major depression, neuropathic pain, ischemia (stroke) and Alzheimer’s.

Based on years of investigation by researchers at Emory and Duke, NeurOp’s drug compounds are based on blocking or activating aspects of the NMDA receptor, a critical signaling pathway in the central nervous system. Through this platform, the company has identified lead molecules that can act as antidepressants, analgesics and neuro-protective agents.

The total market for drugs that treat pain and depression is estimated to be at least $20 billion, while the global market for ischemia-related intervention is estimated at $15 billion or more per year.